Combination therapy for stubborn chronic graft-versus-host disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new combination of two drugs (an IL6-receptor inhibitor plus belumosudil) for people with chronic graft-versus-host disease that hasn't improved with belumosudil alone. It aims to see if this combination is safe and helpful for controlling cGVHD symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have chronic graft-versus-host disease (cGVHD) that is still active and has not responded well enough to belumosudil.
- You must weigh at least 63 kg (about 139 pounds).
- You need to be able to care for yourself (Karnofsky score of at least 60).
- Your blood cell counts and liver/kidney function must be within acceptable ranges.
- If you are of childbearing potential, you must agree to use two forms of birth control and not become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (belumosudil and ruxolitinib) for people with chronic graft-versus-host disease (cGvHD) that has not improved with steroid treatment. The goal is to see if this combination can better control the condition.
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
This trial tests an experimental drug called Iguratimod for people with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see if the drug can safely control cGVHD symptoms when other treatments haven't worked well enough.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.